Background {#Sec1}
==========

Dissemination of life-threatening infections caused by β-lactamase-producing pathogens is a major setback to antimicrobial therapy. The widespread use of carbapenems has resulted in the emergence of carbapenemases, conferring resistance against carbapenem drugs \[[@CR1]--[@CR3]\]. Resistance to carbapenems is worrisome because of the very limited therapeutic options available to treat resistant infections \[[@CR4], [@CR5]\]. The diverse mechanisms of resistance to imipenem include AmpC enzymes accompanied by membrane porin alterations and upregulation of efflux pumps \[[@CR5], [@CR6]\]. The second phenomenon is carbapenem hydrolysis by carbapenemases \[[@CR7]--[@CR9]\]. The epicentre for the emergence of carbapenemases and that of extended spectrum beta lactamases (ESBLs) were different, but the association of their genes is apparent through some studies, where ESBL genes are found to exist in MBL-producing isolates \[[@CR10]\].

Among carbapenemases, metallo-β-lactamases (MBLs) are of prime importance for the region under study because of the emergence of new variants of MBL, such as New Delhi metallo-β-lactamase (NDM) \[[@CR11]\] and various IMP variants from the subcontinent. MBLs belong to class B carbapenemases according to the Ambler classification system \[[@CR12]\]. *bla*~IMP~, *bla*~NDM~ and *bla*~VIM~ are important MBL gene clusters that are carried by mobile plasmids compatible with a vast array of clinically important pathogens \[[@CR13], [@CR14]\]. In addition, oxacillinases belonging to class D include serine β-lactamases and are known to be associated primarily with *Enterobacteriaceae* carbapenem-resistant epidemics.

With more than 37 types of IMP carbapenemases known \[[@CR15]\], IMP-1 was the first to be reported in Japan in 1991\[[@CR16]\]. IMP-4-type enzymes, first discovered in Hong Kong during the 2000s \[[@CR17]\], were later found to be responsible for an outbreak in 2005 in Melbourne, Australia \[[@CR18]\]. The dissemination of resistance genes from *Serratia* spp. and *Pseudomonas aeruginosa* to other members of *Enterobacteriaceae* caused these genes to become endemic in Australia. Approximately 20 different subtypes of IMP enzymes have been described to be associated with *Pseudomonas* spp., *Acinetobacter* spp. and *Enterobacteriaceae* infections throughout the globe \[[@CR19]\].

The first case of VIM-1 enzyme-conferred resistance was reported in 1999 in Verona, Italy \[[@CR20]\]. With reports of VIM-2 being highly prevalent in Europe, Asia, America and Africa \[[@CR21]\], a recent global surveillance study reported four new variants of VIM \[[@CR22]\]. After their discovery in New Delhi in 2009 \[[@CR23]\], NDM-1-producing *Klebsiella pneumoniae* and *E. coli* have been widely reported throughout the globe, including various European countries as well as China, Kenya, Japan, Algeria and Syria \[[@CR24]--[@CR27]\]. A research study has indicated dissemination of the NDM-1 carbapenemase gene through horizontal gene transfer in Pakistan, India and the UK \[[@CR28]\].

The rise in carbapenem resistance in Asian countries has been evident, as reported imipenem resistance rose from 20% in the Philippines \[[@CR29]\] to 40% in Vietnam \[[@CR30]\]. Recently, \> 50% carbapenem-resistant *Klebsiella pneumoniae* isolates have been recorded in India \[[@CR31]\]. With the first report of emergence among *Acinetobacter baumannii* clinical isolates in Scotland in 1985 \[[@CR32]\], plasmid-borne OXA-48 carbapenemases were reported to be highly disseminated in isolates from 18 countries in Europe and Africa \[[@CR33]\].

The resistance pattern of metallo-β-lactamases in Pakistan has not been widely studied. In Pakistan, imipenem was only rarely available prior to the year 2000 \[[@CR34]\]. Later, carbapenem resistance was reported mainly in *P. aeruginosa* in Lahore and Karachi \[[@CR35], [@CR36]\]. A report from Rawalpindi confirmed that 78% of isolates were MBL producers, with major incidence of MBL production in *Acinetobacter baumannii* and *Pseudomonas aeruginosa* \[[@CR37]\].

A very limited number of reports have been published from Pakistan that are based on molecular analysis of genes acquired by carbapenem-resistant isolates. This study aimed to determine the incidence of MBLs through phenotypic and genotypic analyses. Moreover, this study is based on the detection of the gene variants responsible for resistance to carbapenem drugs. To the best of our knowledge, this is the first study from Lahore on the molecular epidemiology and coexistence of *bla*~ESBLs~ and *bla*~MBLs~.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Microbiological testing was conducted at the pathology laboratory of Allama Iqbal Medical College Lahore from July 2015 to July 2017. The study was approved by the Ethical Committee of Citilab and Research Centre Pakistan (CitiLab and Research Centre Ref \# 30th − 15 CLRC/ 30th). The segment of the work based on molecular analysis was carried out at the Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore.

Bacterial isolates {#Sec4}
------------------

A total of 3000 samples were obtained from clinical samples. All clinical specimens were subjected to isolation and identification of significant pathogens according to CLSI procedures (CLSI 2015, 2016). Among 2000 cultures with positive growth, 924 gram negative isolates bacilli were further screened for acquisition of imipenem resistance. On the basis of antibiotic susceptibility patterns, 142 isolates resistant to imipenem were further analysed by molecular tools. Identification of bacterial isolates was performed on the basis of culture characteristics, gram staining and conventional biochemical tests. Confirmation of gram-negative isolates was performed by API 20 NE identification strips (bioMerieux, France). The identified strains were stored in 30% glycerol broth at − 70 °C. Isolates were obtained from wound infections (*n* = 487), urine samples (*n* = 187), sputum samples (*n* = 90), tips and catheters (*n* = 47), fluids and effusions (*n* = 44) and others, including tissue samples, bone samples, and vaginal swabs (*n* = 57) (Table [3](#Tab3){ref-type="table"}).

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

Antimicrobial susceptibility testing (AST) for all isolates was carried out by the Kirby-Bauer method \[[@CR38]\] on Mueller-Hinton agar plates (Oxoid) as per Clinical and Laboratory Standard Institute (CLSI, 2016) recommendations. The antibiotic panel used in screening of the cultures was specific for gram-negative bacteria: penicillins (amoxicillin 30 μg, amoxicillin-clavulanic acid 40 μg, and piperacillin-tazobactam 30 μg), monobactam (aztreonam 30 μg), extended-spectrum cephalosporins (ceftriaxone 30 μg, cefepime 30 μg, cefotaxime 30 μg, cefoxitin 30 μg, and ceftazidime 30 μg), carbapenems (imipenem 30 μg), aminoglycosides (amikacin 30 μg and gentamicin 30 μg), quinolone (ciprofloxacin 30 μg) and trimethoprim-sulfamethoxazole (40 μg). The results of the susceptibility testing were used to calculate the multiple antibiotic resistance (MAR) index for the clinical isolates in order to estimate drug resistance trends and the emergence of new resistant isolates.

Phenotypic detection of MBLs {#Sec6}
----------------------------

Phenotypic detection of MBLs was based on three tests according to the CLSI guidelines (2015--2016). The combination disc test, using a disc of imipenem and imipenem with incorporated EDTA, was performed as per the method used by *Wadekar, Anuradha* \[[@CR39]\]. A modified Hodge test (MHT) was performed according to the method used by Kumar et al. \[[@CR40]\]. The results for each type of isolate were interpreted according to the criteria defined in CLSI 2016. All antibiotics were obtained from Oxoid, Inc. (Canada). E-strips with IMI and IMP/EDTA were used for epsilometer confirmation of MBLs according to the manufacturer's instructions (Liofilchem®).

Molecular characterization of MBLs {#Sec7}
----------------------------------

### DNA template preparation for PCR {#Sec8}

The template DNA was extracted from isolates using previously described methods \[[@CR41]\]. Briefly, a single colony of bacterial isolate was immersed in low TE, and the suspension was boiled for 10 min. The bacterial cell emulsion was centrifuged, and DNA in the supernatant was directly used as a template for PCR amplification.

### Detection of ESBL and MBL genes {#Sec9}

All of the positive MBL isolates based on phenotypic detection (*n* = 123) were further confirmed by singleplex and multiplex colony PCR. Multiplex PCR for *bla*~TEM~, *bla*~OXA~ and *bla*~SHV~ detection was devised~.~ The primer sequences used for the detection of *bla*~TEM~, *bla*~OXA~ and *bla*~SHV~ genes have been previously reported \[[@CR42]\]. Screening for isolates having the *bla*~IMP-1~ gene and *bla*~VIM~ gene was performed by singleplex PCR using previously reported primers \[[@CR43], [@CR44]\]. The PCR reaction was set up with a 25 μl mixture containing 10X PCR buffer, 2.5 mM mixture of dNTPs, 20 pmol each primer and 2.5 U of Taq polymerase. The amplification conditions were set with an initial denaturation at 95 °C proceeded by 35 cycles of 1 min denaturation at 95 °C, 1.5 min annealing (temperatures mentioned in Table [1](#Tab1){ref-type="table"}), extension for 1 min and final extension for 10 min at 72 °C. The Mg concentration was maintained between 1 and 1.5 mM.Table 1List of the Primers used for the detection of ESBL-Type variant (*bla*~OXA,~ *bla*~TEM~ and *bla*~SHV)~ and MBL-type variants (*bla*~IMP-1~ and *bla*~VIM~)PrimersSequencesAnnealing temperature (Tm ^o^C)ReferencesExpected PCR product*bla* ~*IMP-1*~AGCGCAGCATATTGATTGC\
ACAACCAGATGCTGCCTTACC53.6\[[@CR43]\]587*Bla* ~VIM~ATGGTCGTTATGGCATATC\
TGGGCCGTGTCAGCCAGAT57\[[@CR44]\]510*Bla* ~TEM~CCCCGAAGAAGTCCTTTC\
ATCAGCAATAGTCCCAGC55\[[@CR42]\]500*Bla* ~SHV~AGGGCTTGACTGCCATTTTG\
ATTTGCGTGATTTCATTT55\[[@CR42]\]400*Bla* ~OXA~ATATCTCGCTTGTTGCATCTCC\
AAACCCTTCAGCTCATCC55\[[@CR42]\]600

### Statistical analysis {#Sec10}

The collected demographic data were statistically analysed using the Statistical Package for Social Sciences (SPSS version 23). The proportions of *Acinetobacter* spp*., Pseudomonas* spp. and members of *Enterobacteriaceae* were calculated using the chi-square test and odds ratios (ORs). A *p* value of \< 0.05 was considered statistically significant. The associations among the type of infection, age, gender and type of isolate were calculated.

Results {#Sec11}
=======

Distribution of clinical isolates {#Sec12}
---------------------------------

In this study, the resistance pattern of imipenem-resistant clinical isolates was assessed, and the incidence of MBL production among these isolates was determined. Moreover, the significant gene variants associated with the MBL phenotype were analysed. Demographic factors and sites of infection were major highlights of the statistical data analysis. Out of a total of 942 isolates, the total frequency of imipenem resistance was calculated to be 56.512% (*n* = 512). The highest resistance to imipenem was observed for *Acinetobacter* spp., at 61.89%. *Pseudomonas* spp. ranked second in terms of the acquisition of imipenem resistance, with a frequency of 61.89%, followed by *Klebsiella* spp. (50.26%) and *Escherichia coli* (37.97%). Males were found to be more prone to the acquisition of imipenem-resistant infections (60.69%) compared to females (39.31%). The infectivity rates varied between different age groups, with the maximum mean observed among individuals of the age group 20--40 years. The mean age of individuals acquiring MBL infection was 30 years. Wound infections were found to be the most dominant type of infection (51.70%), followed by urinary tract infections (19.86%), respiratory tract infections (9.6%), and infections associated with indwelling catheters (5.2%).

Antibiotic susceptibility testing of MBL isolates {#Sec13}
-------------------------------------------------

The panel of antibiotics recommended according to CLSI 2016 guidelines was applied for all isolates belonging to *Enterobacteriaceae, Pseudomonas* spp. and *Acinetobacter* spp. *Escherichia coli* and *Klebsiella* spp. exhibited susceptibility to gentamycin and piperacillin-tazobactam (23%), amikacin (16%) and sulfamethoxazole/trimethoprim (15%). All the generations of cephalosporins, carbapenem and monobactams showed a complete resistance pattern. *Pseudomonas* spp. and *Acinetobacter* spp. presented susceptibility to amikacin and aztreonam (12%), piperacillin-tazobactam (8%), sulfamethoxazole/trimethoprim and gentamycin (7%) and ciprofloxacin (3%). Multiple antibiotic resistance (MAR) index values for \> 50% of the isolates fell in the range of 0.81--1.00, and 86% of the *Pseudomonas* spp. isolates fell in the range of 0.91--1.0. *E. coli* predominantly had a MAR index value of 0.91--1. A total of 75% of the *Klebsiella* spp. isolates had a MAR index value ranging between 0.81 and 1.

Phenotypic detection of MBLs {#Sec14}
----------------------------

Out of the 906 isolates analysed, 142 randomly selected isolates were suspected to produce metallo-β-lactamases. Among these isolates, 63.38% (*n* = 90) revealed a positive combination disc test, whereas 36.61% (*n* = 52) remained non-determinable by CDST. A total of 86.61% (*n* = 123) of the isolates were confirmed to be MBL producers through the modified Hodge test with meropenem. However, the modified Hodge test with imipenem detected 78.17% (*n* = 111) of the isolates as positive for MBL production and 22.53% (*n* = 32) as negative for MBL production. A total of 68% (*n* = 96%) of the strains were confirmed to exhibit the MBL phenotype through the epsilometer test (E-test).

Multiplex PCR for *bla*~OXA~, *bla*~TEM~, *bla*~SHV,~*bla*~IMP~ and *bla*~VIM~ {#Sec15}
------------------------------------------------------------------------------

The presence of *bla*~OXA~, *bla*~TEM~ and *bla*~SHV~ genes was confirmed in 57.74% (*n* = 82%) of MBL-producing strains by multiplex PCR. The existence of the *bla*~TEM~ gene in MBL-producing isolates was found to be the most prevalent, at 46%, followed by the *bla*~SHV~ gene (34%) and *bla*~*OXA*~ gene (24%). *bla*~IMP-1~ and bla~*VIM*~ genes were detected in 12.5% (*n* = 18) and 7% (*n* = 10) of strains, respectively. The coexistence of all these genes was determined by multiplex PCR. In total, 60% (49/82) of the MBL-positive strains were found to have the *bla*~OXA~, *bla*~TEM~ and *bla*~SHV~ genes in coexistence with each other. The *bla*~TEM~ gene was found to coexist with *bla*~*OXA*~*-type* variants in 21% (*n* = 30) of the MBL producers. The combination of *bla*~TEM~ and *bla*~SHV~ was detected to be the most common, as exhibited by 24% of the strains. The coexistence of *bla*~OXA~ and *bla*~SHV~ genes was observed in 12% of the total isolates. The three genes *bla*~TEM,~ *bla*~OXA~ and *bla*~SHV~ were found to coexist in 9% of the strains (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Frequencies of different gene variants (*TEM, SHV, OXA, VIM, IMP*) in MBL producing clinical isolates. The presence of genes *bla*~OXA~, *bla*~TEM~, *bla*~SHV~ *bla*~IMP-1~and bla~*VIM*~was detected in MBL strains through PCR

### Statistical analysis {#Sec16}

Statistical analysis was performed with SPSS version 23.0 individually for all groups of isolates, including *Escherichia coli*, *Klebsiella* spp., *Acinetobacter* spp. and *Pseudomonas* spp. (Table [2](#Tab2){ref-type="table"}). The associations among demographic variables, including age, gender and type of infections, were determined by calculating odd ratios and performing the chi-square test. A *p*-value of \< 0.05 was considered statistically significant (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).Table 2Comparison of Carbapenem resistant isolates between different age groupsAge (years)*No.* of IsolatesImipenemChi valueOR (95% CI)*p*-valueRS*Escherchia coli*1--954 (80%)1 (20%)--2.28 \[0.23--22.87\]0.64310--1974 (57.14%)3 (42.85%)0.758 \[0.157--3.66\]0.70420--293815 (39.47%)23 (60.52%)10.100.317 \[0.153--0.657\]0.00130--39299 (31.03%)20 (68.96%)7.850.308 \[0.132--0.723\]0.00540--493413 (38.23%)21 (61.76%)2.450.537 \[0.245--1.176\]0.11750--593211 (34.37%)21 (65.62%)4.580.414 \[0.182--0.940\]0.03260--69268 (30.76%)18 (69.23%)5.690.316 \[0.120--0.831\]0.01770--7995 (55.55%)4 (44.44%)--0.809 \[0.177--3.69\]1.000\> 7972 (28.57%)5 (71.42%)--0.150 \[0.018--1.237\]0.145*Acinetobacter* spp.1--9118 (66.66%)4 (33.33%)1.2521.8 \[0.638--5.072\]0.99910--192518 (72%)7 (28%)3.142.015 \[0.92--4.41\]0.26420--293929 (74.35%)10 (25.64%)8.052.94 \[1.37--6.33\]0.07630--394231 (73.80%)11 (26.19%)0.561.33 \[0.633--2.79\]0.00440--493821 (55.26%)17 (44.74%)6.182.94 \[1.28--6.73\]0.45150--593424 (70.58%)10 (29.41%)--3.87 \[1.26--11.81\]0.00960--692015 (75%)5 (25%)--1.031 \[0.23--4.53\]0.02670--79106 (60%)4 (40%)--0.999\> 7944 (100%)0 (0%)*Klebsiella* spp.1--9116 (54.54%)5 (45.45)0.8700.505 \[0.119--2.145\]0.35110--19106 (60%)4 (40%)--0.857 \[0.220--3.343\]1.00020--294022 (55%)18 (45%)1.0400.695 \[0.345--1.401\]0.82430--394119 (46.34%)22 (53.65%)1.520.645 \[0.320--1.299\]0.21840--492615 (57.69%)11 (42.30%)0.7491.458 \[0.619--3.43\]0.38750--59268 (30.76%)18 (69.23%)5.2300.356 \[0.143--0.883\]0.02260--69199 (47.36%)10 (52.63)0.0970.851 \[0.309--2.343\]0.75570--79118 (72.72%)3 (27.27%)--2.286 \[0.493--10.605\]0.466\> 7952 (40%)3 (60%)--0.417 \[0.051--3.435\]0.608*Pseudomonas* spp.1--996 (66.67%)3 (33.34%)--1.05 \[0.22--5.13\]1.00010--193420 (58.83%)14 (41.17%)0.4970.71 \[0.28--1.82\]0.48120--297554 (72%)21 (28%)5.0932.02 \[1.09--3.74\]0.02430--396138 (62.29%)23 (37.70%)2.1271.59 \[0.85--3.00\]0.14540--494423 (52.27%)21 (47.72)0.1301.14 \[0.56--2.31\]0.71850--595130 (58.83%)21 (41.17%)1.9171.63 \[0.81--3.25\]0.16660--692514 (56%)11 (44%)0.4101.35 \[0.54--3.41\]0.52270--7963 (50%)3 (50%)--0.63 \[0.11--3.66\]0.670\> 7922 (100%)0----0.477*\*OR* Odd ratio&\*\* *p* value \< 0.05 is considered as statistically significantTable 3Association of imipenem resistant isolates with type of clinical specimensIsolateSample(*N*)ImipenemChi valueOR*p*-valueRS*Escherichia coli*Wound65224323.0130.276 \[0.159--0.478\]0.000Fluids & Effusion13310--0.123 \[0.027--0.553\]0.007Tips & Catheters651--1.833 \[0.192--17.48\]1.00Urine7934450.8940.756 \[0.422--1.351\]0.344Sputum12570.0960.824 \[0.242--2.806\]0.757Others14410--0.403 \[0.290--0.559\]0.070*Acinetobacter* spp.Wound13092387.161.79 \[1.16--2.75\]0.006Fluids & Effusion13112--6.67 \[1.26--35.28\]0.021Tips & Catheters221750.1711.32 \[0.35--4.97\]0.679Urine2111100.2651.27 \[0.51--3.15\]0.606Sputum2515102.732.17 \[0.85--5.50\]0.098Others13103--4.38 \[1.05--18.17\]0.056*Klebsiella* spp.Wound7143280.0040.983 \[0.59--1.64\]0.947Fluids & Effusion11650.0310.88 \[0.22--3.49\]0.861Tips & Catheters1073--0.75 \[0.16--3.52\]0.700Urine5825330.5340.79 \[0.43--1.48\]0.465Sputum3013170.1100.86 \[0.36--2.06\]0.740Others1046--0.59 \[0.15--2.35\]0.504*Pseudomonas* spp.Wound221142791.841.29 \[0.89--1.85\]0.174Fluids & Effusion752--2.12 \[0.36--12.38\]0.680Tips & Catheters963--0.62 \[0.13--2.99\]0.674Urine2919104.6692.44 \[1.06--5.58\]0.031Sputum239140.5470.69 \[0.27--1.81\]0.459Others201190.2101.29 \[0.43--3.84\]0.647\**OR* Odd ratio&\*\* *p* value \< 0.05 is considered as statistically significantTable 4Comparison of infection rate between male and femaleIsolatesGender(*N*)ImipenemChi valueOR\**p*-value\*\*RS*Escherichia coli*Male10641650.00671.025 \[0.57--1.85\]0.934Female843252*Acinetobacter* spp.Male136944241.054.51 \[2.81--7.24\]0.0001Female9063127*Klebsiella* spp.Male9757404.671.87 \[1.058--3.328\]0.03Female954154*Pseudomonas* spp.Male203125780.00170.98 \[0.61--1.59\]0.483Female1106842*\*OR* Odd ratio&\*\* *p* value \< 0.05 is considered as statistically significant

Discussion {#Sec17}
==========

Pakistan is a country where empirical drug therapy and misuse of antibiotics are common practice. Poor sanitation, filthy practices in clinical settings, and ill-informed health care workers are factors in the dissemination of nosocomial pathogensto the community. Routinely used second-generation drugs are quickly being replaced by drugs of last resort, and this situation is ultimately an enduring threat to mankind. According to one estimate, first-line antibiotic-resistant pathogens account for 25,692 neonatal deaths annually in Pakistan \[[@CR45]\]. Resistance to carbapenems has been significantly observed in Asian countries, including Pakistan \[[@CR30], [@CR46], [@CR47]\]. At present, numerous reports of MBL producers and ESBL producers from Pakistan present clinical catastrophes and alarming health issues \[[@CR41], [@CR48], [@CR49]\]. The present study demonstrates the frequency of imipenem resistance among clinical isolates and the incidence of MBLS producers associated with imipenem resistance in connection with various demographic factors and types of infection. The frequency of imipenem resistance in our study was 56%, which is significantly higher than the data reported from Asian countries in the last decade (2002--2012), with one epidemiological study reporting 1.9% resistance to imipenem and 2.4% resistance to meropenem \[[@CR4]\].

Comparison of the antibiotic resistance profiles of all the pathogens with those reported in other recent studies has revealed relatively similar patterns. The resistance pattern of *Acinetobacter* spp. to imipenem in our study (61.89%) is in conformity with reports by Anwar et al., but a lower rate (77.5%) of imipenem resistance in this region was reported by Shamim et al. \[[@CR50]\]. *Acinetobacter* spp., the pathogen renowned for hospital-acquired infections, was predominantly found to be associated with wound infections and was the causative agent of 92% infections associated with imipenem resistance. *Pseudomonas* spp. was the second most prominent pathogen associated with the acquisition of imipenem resistance, with a frequency of 61.89%, and has been noted in other reports from Pakistan, presenting imipenem resistance rates of 13.42% in 2011 and of 28% and 49.5% in 2015, thus demonstrating a sharp rise in the frequency of imipenem resistance \[[@CR49], [@CR51], [@CR52]\]. The victims of *Pseudomonas* spp. infections were found predominantly in the group of patients with post-burn infections. This finding is in conformity with studies on invasive burn wound infections that document *P. aeruginosa* as a leading pathogen among gram-negative organisms \[[@CR53], [@CR54]\]. Wound infections were particularly found to be associated with *Acinetobacter* spp. (OR = 1.79 \[1.16--2.75\]) and *Pseudomonas* spp. \*OR = 1.29 \[0.89--1.85\]).

The incidence of MBL among imipenem-resistant *Acinetobacter* spp. was calculated to be 89%, which is comparable to that reported in a study by Anwar et al., presenting a frequency of 83.3% MBLs among carbapenem-resistant isolates \[[@CR55]\]. A total of 78% of the imipenem-resistant *Pseudomonas* spp. isolates were detected to be MBL producers by the MHT test, representing a lower incidence compared to the study by Shan et al. that stated the incidence rate to be 87.5% \[[@CR49]\].

Our study demonstrates the OXA-type variants to be predominantly associated with resistance to imipenem. All of the isolates harbouring *bla*~IMP~ were also found to harbour *bla*~TEM~. Despite the uncommon origin of two major groups of β-lactamases, *bla*~ESBL~ and *bla*~MBL,~ their association is imminent according to recent research \[[@CR10]\]. We analysed the isolates for the coexistence of MBL-type and ESBL-type variants. The *bla*~VIM~ gene variant for MBL production was also found to be in coexistence with *bla*~TEM~ and *bla*~SHV~ in *Providencia stuartii* and *Enterobacter* spp. A total of 12.5% isolates were found to coexhibit the *bla*~IMP-1~ and *bla*~SHV~ genes, whereas 10% were positive for the *bla*~*OXA*~ gene along with the *bla*~IMP-1~ gene.

The abovementioned mechanism of coexistence of genes has been reported in *Klebsiella pneumoniae, Escherichia coli, Salmonella* spp*.* and *Enterobacter* spp. \[[@CR56]\]*.* Plasmids containing the *bla*~NDM-1~ gene have been observed to coexhibit genes for CTX-M, TEM-1 and OXA-1 enzymes. Major ESBL and MBL genes, including *bla*~CTX-M~, *bla*~SHV~, *bla*~TEM~, and *bla*~OXA-51~, and genes for the VIM-family and IMP-family, have been reported to coexist in clinically resistant *Acinetobacter baumannii* in Iran \[[@CR57]\]. However, one study concluded that there was no significant relationship between ESBL and MBL production genes \[[@CR57]\]. Ertapenem-resistant, ESBL-producing *Klebsiella pneumoniae* isolates have been reported in Italy and shown to carry novel porin variants that contributed to the reduced susceptibility of isolates to meropenem and imipenem \[[@CR58]\].

The coexistence of the genes for MBL and ESBL variants in our isolates indicates the simultaneity of the emergence of different variants of β-lactamases among pathogens in our clinical settings. This finding also suggests that the resistance against imipenem in our isolates is mediated by MBL-type enzymes along with the overproduction of ESBL-type enzymes, as suggested by other studies \[[@CR5], [@CR7]\]. To the best of our knowledge, this is the first study from Pakistan reporting the coexistence of *bla*~IMP~ with *bla*~TEM~-type and *SHV*-type variants. None of the isolates was found to coexhibit all the tested genes (*bla*~OXA~, *bla*~TEM~, *bla*~SHV~, *bla*~IMP-1~ and *bla*~VIM~).

Conclusion {#Sec18}
==========

In conclusion, ESBL- and MBL-producing bacterial isolates are emerging very rapidly in the region. A great number of carbapenem-resistant clinical bacterial species are resistant to most of the commonly used antibiotics, demonstrating the rise of super-bacteria and their pan-resistance to antimicrobial therapy. Determining the resistance mechanisms and the root cause for their elimination are of great importance. It is also important to implement the routine screening of ESBLs and MBLs in laboratory procedures before antibiotic therapy begins. Further studies are required to specify other types of gene variants prevalent among clinical isolates in our region for the implication of medication in clinical settings.
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